Cenix BioScience and Schering enter new agreement on multiple RNAi-based target validation projects
Cenix BioScience of Dresden, Germany, a specialist in advanced RNA interference (RNAi)-based research services, entered into a new agreement with Schering AG to extend its target validation partnership.
Cenix BioScience of Dresden, Germany, a specialist in advanced RNA interference (RNAi)-based research services, entered into a new agreement with Schering AG to extend its target validation partnership.
The move follows the success of a pilot project started in late 2004, which focused on the application of Cenix' combination of high throughput (HT) RNAi technology with multiplexed, high content phenotypic analyses to efficiently generate detailed in vitro validation data for over 100 target candidates in multiple mammalian cell types.
As a result of this success, the two companies have set new terms under which Schering will outsource up to six more projects of similar type, mandating Cenix to carry out HT-RNAi validation programs in human cells to rapidly and efficiently screen through large collections of target candidate genes previously identified by Schering.
No financial terms were disclosed.